Eosinophilia can identify asthmatic patients who may benefit more significantly from ICS therapy,20 and monoclonal antibodies targeting IgE or the type 2 cytokines (IL‐4, IL‐5 and IL‐13) or alarmins (IL‐33, TSLP) benefit patients with the ‘Type‐2‐high’ phenotype of asthma.3, 21. The gene discussed is IL5; the disease is asthma.